Breaking News

CDA served more than 500 notices and show cause notices on violation of building by-laws

Islamabad, December 21, 2019 (PPI-OT): Capital Development Authority (CDA) has served more than 500 notices and show cause notices to the owners of the commercial premises on violation of building by-laws, operating in buildings without obtaining completion certificates and other building violations. The action is being taken in the light of survey conducted by the BCS directorate for determining building violations and data compilation regarding commercial premises in the sectorial area city.

During the survey more than 3000 commercial premises situated in Blue Area, Marakiz, Class-III markets and petrol pumps were inspected and required data was collected and compiled. In the light of collected data, compoundable and non-compoundable violations are being segregated so that action according to building bye-laws could be initiated. In this connection, more than 500 notices/show-cause notices have been issued to violators while few premises have also been sealed during the last weeks.

Moreover, owners of the premises who have not yet obtained building completion certificate or have not obtained approval of building plans from the Authority are being compelled to complete the codel formalities for issuance of completion certificates and approval of building plans. The exercise of the authority will be resulted in handsome revenue generation in respect of compoundable violations. It is pertinent to mention here that this exercise has not only resulted in consolidated data compilation regarding commercial premises in the city but will also help exercise building control and implementation of relevant building by-laws in the city.

For more information, contact:
Public Relations Directorate
Capital Development Authority (CDA)
Main Office, G-7/4, Islamabad
Tel: +92-51-9252614
Email: getreply@cda.gov.pk
Website: www.cda.gov.pk

Check Also

Nyxoah Reports First Quarter 2024 Financial and Operating Results

REGULATED INFORMATION Nyxoah Reports First Quarter 2024 Financial and Operating Results Announced DREAM U.S. pivotal study achieved primary endpoints On track for FDA approval as early as end of 2024 Mont-Saint-Guibert, Belgium – May 14, 2024 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah� or the “Company�), a medical technology company […]